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Cellular responses to viral infection are signaled by
double-stranded (ds) RNA, which is not found in sub-
stantial amounts in uninfected cells. Although cellular
dsRNA-binding proteins have been described, their
characterization is incomplete. We show that dsRNA-
binding proteins are prominent autoantigens. Sera from
B6 and B10.S mice with pristane-induced lupus and hu-
man autoimmune sera immunoprecipitated a novel set
of 130-, 110-, 90-, 80-, and 45-kDa proteins. The proteins
were all major cellular poly(IC)-binding factors. N-ter-
minal amino acid sequences of p110 and p90 were iden-
tical and matched nuclear factor (NF) 90 and M phase
phosphoprotein 4. p45 and p90 were identified as the
NF45zNF90 complex, which binds the interleukin-2 pro-
moter as well as certain highly structured viral RNAs.
NF90zNF45 and M phase phosphoprotein 4 belong to a
large group of proteins with conserved dsRNA-binding
motifs. Besides binding dsRNA, NF90zNF45, p110, and
p130 had single-stranded and dsDNA binding activity.
Some sera contained autoantibodies whose binding was
inhibited by poly(IC) but not single-stranded DNA or
vice versa, suggesting that the DNA- and RNA-binding
sites are different. These autoantibodies will be useful
probes of the function of dsRNA-binding proteins. Their
interaction with dsRNA, an immunological adjuvant,
also could promote autoimmunity.
The existence of viral infection is signaled by the production
of double-stranded (ds)1 RNA, which is not found in substantial
amounts in uninfected cells (1). The presence of dsRNA induces
interferon production and the expression of a dsRNA-specific
adenosine deaminase (2, 3) and the dsRNA-dependent serine/
threonine kinase PKR (4). PKR phosphorylates eukaryotic pro-
tein synthesis initiation factor 2 and IkB, resulting in a global
inhibition of protein synthesis and activation of NFkB, respec-
tively (5, 6). It also activates interferon regulatory factor 1 (7).
The cellular machinery for recognition of dsRNA has come
under increasingly close scrutiny. Structured viral RNAs, such
as the adenovirus virus-associated (VA) RNAII, are recognized
by cellular dsRNA-binding proteins such as RNA helicase A,
the NF90zNF45 dimer, and other less well defined factors (8).
The components of the dsRNA recognition apparatus and their
functions are poorly characterized, although some of them
carry one or more copies of a conserved dsRNA-binding motif
(9). Interestingly, although the NF90 protein carries two copies
of this motif, it also binds to a DNA element found in the
interleukin-2 promoter (10, 11). However, the significance of
this dual nucleic acid binding activity is not known.
Sera from patients or mice with systemic autoimmune dis-
eases have been instrumental in defining the function of the
proteins associated with small nuclear ribonucleoprotein par-
ticles (12). One of these, the La (SS-B) autoantigen has dsRNA
binding activity (13), but autoantibodies against the major
dsRNA-binding proteins that bind to VA RNAII have not been
reported. In the present study autoantibodies specific for a
family of dsRNA-binding factors, including those implicated in
VA RNAII binding, were identified. Interactions between these
factors were characterized along with their nucleic acid binding
properties.
EXPERIMENTAL PROCEDURES
Treatment of Mice—Four-week-old female SJL/J, A.SW, B10.S,
C57BL/10 (B10), BALB/c ByJ, BALB.B, BALB.K, C57BL/6J (B6), and
B6H2k mice were purchased from Jackson Laboratory (Bar Harbor,
ME) and housed conventionally. Additional B6 mice were purchased
from Charles River Laboratories (Wilmington, MA). At 10 weeks of age,
5–20 mice/strain were injected with 0.5 ml of pristane intraperitoneal
or with an equal volume of sterile phosphate-buffered saline (PBS) as a
control. Sera were collected from the tail vein before injection, at 2 and
4 weeks afterward and at 1-month intervals thereafter. Sera from
DBA/1 mice 6 months after pristane treatment were a gift of Dr. Paul H.
Wooley (Wayne State University, Detroit, MI).
Radiolabeling and Immunoprecipitation—Autoantibodies to cellular
proteins in murine and human sera were analyzed by immunoprecipi-
tation of 35S-radiolabeled K562 cell extract using 3 ml of murine serum/
sample as described (14). Specificity was confirmed using human anti-
nRNP/Sm, Su, and ribosomal P reference sera.
Immunoblotting—IgG from 10 ml of human serum YM was cross-
linked to 50 ml (v/v) of protein A-Sepharose beads with dimethyl pime-
limidate as described (15). K562 cells were sonicated in NET/Nonidet
P-40 (150 mM NaCl, 2 mM EDTA, 50 mM Tris, pH 7.5, 0.5% Nonidet
P-40) at a concentration of 4 3 107/ml and cleared by centrifugation.
Cell extract from 108 cells was incubated with patient YM IgG-protein
A-Sepharose beads for 1 h at 4 °C. The p130, p110, p90, and p45
antigens were affinity-purified, fractionated by SDS-PAGE, and trans-
ferred to nitrocellulose. Strips were probed with sera from pristane or
PBS-treated mice, human autoimmune sera, or normal human serum
(1:2000 dilution). They then were incubated with 1:3000 alkaline phos-
phatase-conjugated goat anti-mouse IgG or goat anti-human IgG (g-
chain-specific, Southern Biotechnology, Birmingham, AL) and devel-
* This work was supported in part by United States Public Health
Service Research Grants R01-AR44731, AR40391, P60-AR30701, and
T32-AR7416. The costs of publication of this article were defrayed in
part by the payment of page charges. This article must therefore be
hereby marked “advertisement” in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶ Arthritis Foundation Postdoctoral Fellow.
i To whom correspondence should be addressed: Div. of Rheumatol-
ogy and Clinical Immunology, University of Florida, P.O. Box 100221,
Gainesville, FL 32610. Tel.: 352-392-8600; Fax: 352-392-8483; E-mail:
reevewh@medicine.ufl.edu.
1 The abbreviations used are: ds, double-stranded; NF, nuclear factor;
ss, single-stranded; VA, virus-associated; B6, C57BL/6 mice; MPP4, M
phase phosphoprotein 4; PKR, dsRNA-dependent protein kinase; PBS,
phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 274, No. 49, Issue of December 3, pp. 34598–34604, 1999
© 1999 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org34598
This is an Open Access article under the CC BY license.
oped using the Western-Star chemiluminescent system (Tropix,
Bedford, MA).
To verify the identities of the antigens, proteins immunoprecipitated
by human sera YM and EB were fractionated by SDS-PAGE, trans-
ferred to nitrocellulose, and probed with serum from a pristane-treated
B6 mouse containing antibodies to p110, p90, and p45 or with PBS-
treated mouse serum. In addition, strips were probed with serial B6 or
B10.S sera obtained 1–6 months after pristane treatment to examine
the onset of autoantibody production.
Affinity Purification of Autoantibodies—The p130, p110, p90, and
p45 proteins were affinity-purified from K562 cell extract using human
autoimmune serum, fractionated by SDS-PAGE, and transferred to a
nitrocellulose filter as above. After Ponceau red staining, the p130,
p110, p90, and p45 bands and unrelated areas were cut from the filter.
Strips were incubated with 2 ml of 1:1000 B6 or B10.S sera for 1 h at
22 °C and washed with TBS-Tween 20 (20 mM Tris-HCl, 150 mM NaCl,
0.1% Tween 20). Bound antibodies were eluted twice with 300 ml of 50
mM glycine, 150 mM NaCl, pH 2.9. After adjusting the pH to 7.5 with 0.2
M Na2HPO4, affinity-purified antibodies were used to reprobe strips
with bound p130, p110, p90, and p45.
N-terminal Amino Acid Sequence—The p130, p110, p90, and p45
proteins from K562 cell extract were affinity-purified with human se-
rum bound to protein A-Sepharose beads (see above), fractionated by
SDS-PAGE, and transferred to polyvinylidene difluoride membrane.
The membrane was stained with 0.1% Coomassie Blue in 40% methanol
and destained with 50% methanol, and the proteins were subjected to
N-terminal amino acid sequencing using a Perkin-Elmer/ABI Procise
model 492 protein/peptide sequencer (University of North Carolina/
Program in Molecular Biology and Biotechnology Micro Protein Chem-
istry Facility). Proteins exhibiting homology with the N-terminal se-
quences were identified using the NCBI advanced BLAST algorithm for
the GenBankTM Data Base.
Enzyme-linked Immunosorbent Assays for Autoantibodies to
NF90zNF45—Full-length recombinant NF45 and NF90 with N-termi-
nal 6-histidine tags were expressed in Escherichia coli and purified by
nickel chelate affinity column as described (10). The wells of microtiter
plates (MaxiSorp, Nunc, Naperville, IL) were coated with 50 ml of 2
mg/ml of purified recombinant NF45 or NF90 in 20 mM Tris-HCl, pH
8.0, for 16 h at 4 °C. Wells were washed with NET/Nonidet P-40 and
blocked with 0.5% bovine serum albumin in NET/Nonidet P-40 for 1 h
at 22 °C followed by incubation with 100 ml of 1:500 mouse serum in
blocking buffer for 2 h. Wells were washed with NET/Nonidet P-40,
incubated with 100 ml of 1:1000 alkaline phosphatase-conjugated goat
anti-mouse IgG for 2 h, and developed.
Poly(IC) and DNA Affinity Chromatography—120 ml (50% v/v) of
poly(IC)-agarose (Amersham Pharmacia Biotech), ssDNA cellulose, or
dsDNA cellulose (Sigma) in TBS-Tween 20 plus 3 mM MgCl2 was
washed three times with starting buffer. The matrix was incubated for
1 h at 4 °C with cell extract from 107 [35S]methionine-labeled K562 cells
in starting buffer plus phenylmethylsulfonyl fluoride and aprotinin and
then washed six times with 1 ml TBS-Tween 20 1 3 mM MgCl2. Proteins
were eluted with 600 ml of 1.5 M NaCl NET/Nonidet P-40 for 20 min at
4 °C. The eluate was spun three times in a microcentrifuge for 5 s, and
the supernatant was transferred to a new tube and adjusted to a final
concentration 0.75 M NaCl. The eluate was immunoprecipitated (30 min
at 4 °C) with 5 ml of human autoimmune serum YM containing anti-
NF45zNF90, anti-Ku 1 nRNP/Sm, or normal human serum, washed
three times with 0.5 M NaCl NET/Nonidet P-40, and washed once with
NET before analyzing by SDS-PAGE.
Inhibition Assay—A microtiter plate was coated with 50 ml of 0.5
mg/ml recombinant NF90 or NF45 at 4 °C for 14 h. Wells were washed
twice with TBS-Tween 20 plus 3 mM MgCl2 and blocked for 1 h with
0.5% bovine serum albumin in the same buffer. Wells coated with NF90
or NF45 were incubated for 3 h at 22 °C with single-stranded (ss) DNA
(from calf thymus, Sigma) or poly(IC) (Sigma) at a concentration of 10,
1, 0.1, 0.01, and 0.001 mg/ml in PBS 1 3 mM MgCl2 or with buffer alone.
Wells were washed three times with TBS-Tween 20 1 3 mM MgCl2,
incubated with murine or human autoimmune sera (1:500–1:10,000) in
0.5% bovine serum albumin TBS-Tween 20, 3 mM MgCl2, and washed
three times with TBS-Tween 20. Wells were incubated for 1 h at 22 °C
with 100 ml of alkaline phosphatase-conjugated goat anti-human or
anti-mouse IgG antibodies (g-chain-specific, 1:1000) and developed us-
ing Sigma 104 substrate. Inhibition was calculated as follows: [(A405 of
wells incubated with buffer alone 2 A405 of wells incubated with ssDNA
or poly(IC)) 4 A405 of wells incubated with buffer alone] 3 100.
RESULTS
Sera from mice treated with pristane contain autoantibodies
against antigens recognized by human systemic lupus erythe-
matosus sera (14, 16). Some are RNA-associated proteins, such
as the components of U1 small nuclear ribonucleoproteins. In
the present study, we investigated a novel set of proteins rec-
ognized by sera from pristane-treated mice and certain human
autoimmune sera. These proteins included some of the major
proteins bound by VA RNAII, indicating that dsRNA-binding
proteins are a novel group of autoantigens.
Autoantibodies to p130, p110, p90, p80, and p45—When sera
from various strains of pristane-treated mice were tested at 6
months, some B6 (Fig. 1, lanes 4–7) and B10.S (lanes 8 and 9)
mouse sera immunoprecipitated a set of 130-, 110-, 90-, 80-,
and 45-kDa proteins. Normal mouse serum (lane 10) did not.
Out of 31 B6 mice treated with pristane, nine (29%) had this
specificity. Among these, four also had anti-nRNP/Sm, two had
anti-ribosomal P, and one had anti-Su antibodies. Two of six
pristane-treated B10.S mice had this specificity, both with
co-existing anti-ribosomal P and anti-Su antibodies. These pro-
teins were not immunoprecipitated by sera from A.SW, BALB/c
ByJ, or SJL/J mice, despite the high frequencies of anti-nRNP/
Sm, Su, or ribosomal P antibodies reported previously in these
strains (14, 16).2
Two human autoimmune sera immunoprecipitated a similar
set of proteins (Fig. 1, lanes 1 and 2), whereas normal human
serum (lane 3) did not. The serum used in lane 1 was from EB,
an Afro-Caribbean patient with systemic lupus erythematosus-
rheumatoid arthritis overlap syndrome, and the serum in lane
2 was from YM, a Japanese patient with scleroderma. All sera
with this specificity immunoprecipitated proteins of ;130, 110,
90, 80, and 45 kDa with the exception of EB (lane 1), which did
not immunoprecipitate the 130- or 80-kDa polypeptides clearly.
The relative intensities of p110, p90, and p45 immunoprecipi-
tated by all sera except EB were comparable. The stronger p90
signal using EB serum was found to be due to the immunopre-
cipitation of two proteins migrating at ;90 kDa. Using differ-
2 M. Satoh, H. B. Richards, V. M. Shaheen, H. Yoshida, M. Shaw, P.
H. Wooley, and W. H. Reeves, submitted for publication.
FIG. 1. Autoimmune sera immunoprecipitate p130, p110, p90,
p80, and p45. 35S-Labeled K562 cell extract was immunoprecipitated
with sera from patients with systemic lupus erythematosus-rheumatoid
arthritis overlap syndrome (patient EB, lane 1) or scleroderma (patient
YM, lane 2) or with normal human serum (N, lane 3). The same extract
was also immunoprecipitated with B6 sera (lanes 4–7), B10.S sera
(lanes 8 and 9) 6 months after pristane treatment or with control mouse
serum (NMS, lane 10). All sera immunoprecipitated p130, p110, p90,
p80, and p45 except for the EB (lane 1), which did not immunoprecipi-
tate p130 or p80 clearly but did immunoprecipitate the other proteins.
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ent gel conditions, the two ;90-kDa bands immunoprecipitated
by EB serum could be resolved (not shown).
Human and Murine Autoimmune Sera Recognize the Same
Antigens—The relationship of the proteins immunoprecipi-
tated by sera from patients EB and YM to those recognized by
sera from B6 or B10.S mice was investigated by Western blot-
ting. The p130, p110, p90, and p45 proteins were affinity-
purified using patient YM IgG-Sepharose, separated by SDS-
PAGE, and transferred to nitrocellulose (Fig. 2A). Blots were
probed with sera from pristane-treated B6 (lanes a–i) or B10.S
(lanes j and k) mice or with sera from PBS-treated B6 mice
(lanes l and m). Additional strips were probed with EB and YM
sera (lanes 1 and 2, respectively), or normal human serum (lane
3). All sera from pristane-treated mice that immunoprecipi-
tated p130, p110, p90, p80, and p45 recognized p110 and p90 by
Western blot (lanes a–i). Many sera also reacted weakly with
p130 and some recognized p80 (lanes a and h) or p45 as well
(lanes a and k). In contrast, the human sera were poorly reac-
tive on immunoblotting. EB serum (Fig. 2A, lane 1) did not
recognize any of the proteins in Western blot, whereas YM
serum reacted weakly with p45. However, unlike the murine
sera, it did not react with p110 or p90 (Fig. 2A, lane 2). Thus,
human autoantibodies recognized mainly native conforma-
tional epitopes.
The identity of the antigens recognized by the human and
murine sera was further verified by immunoprecipitating K562
extract with patient EB or YM serum (Fig. 2B, lanes 1 and 2,
respectively) or with normal human serum (lane 3) followed by
immunoblotting. Blots were probed with sera from a B6 mouse
with anti-p110 and p90 (Fig. 2B, panel a), from a B10.S mouse
with anti-p110, p90, and p45 (panel b), or from a PBS-treated
B6 mouse (panel c). Mouse sera with antibodies to p110, p90,
and/or p45 recognized proteins of the same size that were
immunoprecipitated by human autoimmune sera EB and YM,
confirming that the proteins recognized by the human and
murine autoimmune sera were the same.
p90 and p45 Are NF90zNF45—To identify the proteins rec-
ognized by the human and murine autoimmune sera, N-termi-
nal sequences were obtained from p110 and p90 affinity-puri-
fied on patient YM IgG-protein A-Sepharose. The p110 and p90
proteins had identical N-terminal amino acid sequences: PM-
RIFVND. A homology search identified two proteins with the
same N-terminal sequence: M phase phosphoprotein 4 (MPP4)
and nuclear factor (NF) 90 (Fig. 3). A homologue of MPP4,
Xenopus double-stranded (ds) RNA-binding protein, matched
the N-terminal sequence of p110 and p90 at 7 of 8 positions.
The p90 protein was identified as NF90 on the basis of several
criteria: 1) the sizes were similar, 2) N-terminal amino acid
sequences were identical, 3) sera from rabbits immunized with
NF90 recognized p90 on Western blots (not shown), and 4)
autoimmune sera with anti-p90 recognized recombinant NF90
(see Fig. 6).
Although the N-terminal sequence could not be obtained,
possibly because of a blocked N terminus, p45 was identified as
NF45 on the basis of similar sizes and its physical association
with NF90. NF90 and p45 co-migrated on sucrose gradients,
suggesting that they are physically associated, and NF90 could
be co-immunoprecipitated by affinity-purified anti-p45 anti-
bodies (not shown). Finally, serum from a rabbit immunized
with NF45 recognized p45 on immunoblots and the murine
autoimmune sera containing anti-p45 antibodies were reactive
with recombinant NF45 on Western blots (see Fig. 6). On the
basis of the biochemical and immunological data, we conclude
that p90 and p45 are NF90 and NF45, respectively.
p110, p130, and p80—The identity of the 110-kDa protein is
less certain. Autoantibodies affinity purified from p90 cross-
reacted with p110, and serum from a rabbit immunized with
NF90 recognized the 90- and 110-kDa proteins immunoprecipi-
tated by the human and murine autoimmune sera (not shown).
The 110-kDa protein could be MPP4 (17), which was found to
share an identical N-terminal amino acid sequence with NF90
by aligning the sequences using the BLAST programs. The
reported partial sequences of MPP4 are nearly identical with
NF90. MPP4 is recognized by monoclonal antibodies specific for
the phosphorylated sites of proteins (17, 18) and is a nuclear
protein phosphorylated in M phase thought to be a human
FIG. 2. Immunoblot analysis of the specificities of human and
murine sera. A, p130, p110, p90, and p45 were affinity-purified from
K562 cell extract using patient EB IgG-Sepharose, fractionated by
SDS-PAGE, and transferred to nitrocellulose. Strips were probed with
sera from pristane treated B6 (lanes a–i), or B10.S (lanes j and k) mice
or with PBS-treated B6 sera (lanes l and m). Sera tested in lanes a–k
immunoprecipitated p130, p110, p90, and p45. Note consistent reactiv-
ity with p110 and p90 on the blots. Some sera also were weakly reactive
with p130 and/or p45 (p45, see lanes a and k). Additional strips were
probed with patient EB or YM sera (lanes 1 and 2) or with normal
human serum (lane 3). EB serum was unreactive with any proteins on
membrane whereas YM serum reacted with p45 weakly. B, K562 cell
extract was immunoprecipitated with EB and YM sera (lanes 1 and 2,
respectively) or with normal human serum (lane 3). Proteins were
fractionated by SDS-PAGE, transferred to nitrocellulose membrane,
and probed with sera from a pristane-treated B6 mouse with antibodies
to p110, p90, and p45 (panel a), from a pristane-treated B10.S mouse
with antibodies to p110, p90, and p45 (panel b) or from a PBS-treated
mouse serum (panel c). Mouse sera recognized proteins immunoprecipi-
tated by human autoimmune sera EB and YM.
FIG. 3. Comparison of N-terminal sequences. N-terminal amino
acid sequences of p110 and p90 were aligned with the N-terminal
sequences of MPP4, NF90, and Xenopus dsRNA-binding protein ob-
tained from GenBankTM.
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homologue of Xenopus dsRNA-binding protein. Alternatively,
p110 could be an extended form or precursor of NF90 (see
“Discussion”).
The p130 and p80 polypeptides co-purified with NF45zNF90
on a poly(IC)-agarose column and may be related to
NF45zNF90 (see Fig. 7). It is possible that p80 is a degradation
product of p130, p110, or NF90. However, p130 and p80 are
unlikely to form a stable complex with NF45zNF90 because
patient EB serum did not co-immunoprecipitate p130 or p80
(Fig. 1).
Time Course of Autoantibody Production—The data shown
in Figs. 1–3 suggested that the production of autoantibodies to
p130, p110, p90 (NF90), and p45 (NF45) was tightly linked. For
this reason, we investigated the time course of autoantibody
production by Western blot in sera obtained sequentially from
pristane-treated mice (Fig. 4). Affinity-purified antigens were
probed with sera obtained 1–6 months after pristane treat-
ment of B6 (panels A–D) or B10.S mice (panels E and F).
Antibodies to p110 and NF90 always developed simultaneously
between 2–5 months. Some sera also recognized NF45 (panels
A and F) or p130 (panel E). In the B6 mouse illustrated in panel
A, antibodies to NF90 and p110 were detected at 3 months,
whereas antibodies to NF45 did not appear until 5 months
after pristane treatment.
The time course also was investigated by immunoprecipita-
tion using serial sera from these mice. NF90, NF45, and p110
usually appeared in the immunoprecipitates at the same time.
However, occasionally p110 and NF45 were immunoprecipi-
tated before immunoprecipitation of NF90 was apparent (Fig.
5A). Sera from this B10.S mouse immunoprecipitated p110
plus NF45 at 3 months, followed by an increased amount of
NF45 plus NF90 at 4 months. At 5 months, the mouse devel-
oped autoantibodies against p130. This suggested that NF45
bound both p110 and NF90, a possibility that was investigated
further by using rabbit antiserum against NF45. As shown in
Fig. 5B, anti-NF45 antiserum (lane R45) co-immunoprecipi-
tated both NF90 and p110, further suggesting that NF90zNF45
and p110zNF45 dimers may exist. In contrast, p130 was not
co-immunoprecipitated by anti-NF45, suggesting that it did not
form a stable complex with NF45. This interpretation also was
supported by the fact that p130 could be eluted from poly(IC)-
agarose by 0.5 M NaCl, whereas NF90, NF45, and p110 were
eluted only at higher salt concentrations (not shown). Because
the results of the co-immunoprecipitation studies could be com-
patible with immunological cross-reactivity between NF45 and
other proteins, the specificities of anti-NF45, NF90, and p110
autoantibodies also were examined by Western blot.
Autoantibodies to p110 and NF90 Are Cross-reactive—Sera
from a pristane-treated B6 mouse (Fig. 6, panel a, lane 1) or
from a B10.S mouse (panel b, lane 1) recognized both p110 and
NF90 in Western blot assays. Affinity-purified anti-p110 and
anti-NF90 from the sera bound to both p110 and NF90 (lanes 3
and 4, respectively), suggesting that these autoantibodies were
cross-reactive. The signal from affinity-purified anti-NF45
(panel b, lane 5) was weak under these conditions but appar-
ently specific for NF45. Thus, immunological cross-reactivity is
likely to explain the simultaneous onset of anti-NF90 and
anti-p110 autoantibodies in many sera. These data also lend
further support to the idea that NF45 forms a complex with
NF90 and with p110.
NF45zNF90 complexes bind to dsRNA as well as DNA. NF90
has two copies of a dsRNA-binding motif, binds dsRNA
strongly, and interacts selectively with the adenoviral VA
RNAII, suggesting that it could play a role in regulating the
activity of certain highly structured RNAs along with its pro-
posed role as a DNA-binding protein (10, 8). The nucleic acid
binding properties of proteins recognized by the human and
murine autoimmune sera were examined. Proteins from K562
cell extract were absorbed to dsRNA (poly(IC)-agarose),
ssDNA, or dsDNA cellulose, eluted with salt, and immunopre-
cipitated with autoimmune sera. Immunoprecipitation with
human serum YM (anti-NF45zNF90) is shown in lane 1 of each
panel. Lanes 2 and 3 show immunoprecipitations with human
anti-Ku plus anti-nRNP/Sm serum or normal human serum,
respectively. NF45zNF90 complexes were detected in eluates
from poly(IC)-agarose as reported previously (8), as well as in
eluates from ssDNA and dsDNA cellulose (Fig. 7, lanes 1).
The Ku (p70zp80) complex, which binds to ends of dsDNA or
single to double strand transitions, but not RNA, was used as a
specificity control (lanes 2). Consistent with previous observa-
tions (reviewed in Ref. 19), Ku antigen was detected in eluates
from ssDNA and dsDNA cellulose. However, it was not present
in the eluates from poly(IC)-agarose. Another control antigen,
the U1 small nuclear ribonucleoprotein, could be detected
FIG. 4. Time course of autoantibody production. The p130,
p110, p90, and p45 antigens were affinity-purified from K562 cell ex-
tract, fractionated by SDS-PAGE, and transferred to nitrocellulose.
Strips were probed with serial sera obtained 1, 2, 3, 4, 5, and 6 months
after pristane treatment of B6 mice (A–D) or B10.S mice (E and F).
Positions of the p130, p110, p90, and p45 antigens are indicated.
FIG. 5. NF45 forms complexes with NF90 and p110. A, immuno-
precipitation using sera from a pristane-treated B10.S mouse. Sera
were collected monthly for 6 months and used to immunoprecipitate
proteins from K562 cell extract (lanes 1–6). Immunoprecipitation with
a human reference serum is shown on the left. Positions of p130, p110,
NF90, and NF45 are indicated. B, immunoprecipitation using rabbit
anti-NF45 antiserum. Serum from a rabbit immunized with recombi-
nant NF45 expressed in bacteria immunoprecipitated NF45 as well as
NF90 and p110 (lane RA45). Immunoprecipitation with human refer-
ence serum (YM, positive control) is shown for comparison, as well as
normal human serum (NH) and preimmune rabbit antiserum (NR).
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readily in the unfractionated extract (left panel, see U1-A pro-
tein) but was not present in eluates from any of the three
affinity matrices. Thus, binding of the NF45zNF90 complex to
dsRNA as well as ssDNA and dsDNA was confirmed. The p130
and p80 proteins also were eluted from poly(IC)-agarose. Al-
though there was evidence that p130 interacts with ssDNA and
dsDNA, we cannot be certain whether this protein binds DNA
or dsRNA independently or because of an interaction with
NF45zNF90.
Binding of Autoantibodies to NF90 Is Inhibited by ssDNA
and Poly(IC)—The nucleic acid-binding site of Ku antigen is a
target of autoantibodies (20). Because the NF45zNF90 dimer
binds to dsRNA as well as DNA, we examined whether nucleic
acid binding could block autoantibody recognition. The binding
of antibodies to NF90 in two B6 mouse sera (Fig. 8, A and B)
was inhibited by poly(IC) in a dose-dependent manner, but only
weakly by ssDNA. The binding of other sera to NF90 was
inhibited by both poly(IC) and ssDNA or by ssDNA alone (Figs.
8, C and D). Neither ssDNA nor poly(IC) inhibited binding to
NF45, suggesting that NF45 does not bind nucleic acids by
itself or that the nucleic acid-binding site is not recognized by
autoantibodies. Of the 11 anti-NF90zNF45 positive sera from
pristane-treated mice tested, the binding of four to NF90 was
inhibited .10% by ssDNA (Fig. 8C, left). In contrast, the bind-
ing of these sera to NF45 was not inhibited by ssDNA (Fig. 8C,
right). Poly(IC) inhibited the binding of 7/11 sera by .10%.
Although both ssDNA and poly(IC) inhibited the binding of
many sera, in some cases only one of the two nucleic acids
inhibited (Fig. 8D). In the case of human autoimmune serum
YM, only poly(IC) inhibited binding to NF90. These data sug-
gest that the DNA and dsRNA-binding sites of NF90 are not
identical. Moreover, anti-NF90 autoantibodies recognized
epitope(s) near the DNA- and dsRNA-binding sites, consistent
with the idea that autoantibodies often recognize functional
sites (21).
DISCUSSION
Double-stranded RNA is a signature of viral infection, and
host cells have evolved defense mechanisms for detecting and
responding to it. Several dsRNA-binding proteins, some shar-
ing a conserved dsRNA-binding motif, have been identified (9).
In this study, we present evidence that prominent dsRNA-
binding proteins of 130, 110, 90 (NF90), 80, and 45 (NF45) kDa
are recognized by human and murine autoantibodies. Biochemical
studies suggest that at least some these proteins are physically
associated and that the 90- and 110-kDa proteins share significant
sequence homology and immunological cross-reactivity.
dsRNA-binding Proteins: a Novel Class of Autoantigens—A
variety of DNA-protein and RNA-protein antigens are recog-
nized by autoantibodies in systemic autoimmune diseases (12,
22). However, dsRNA-binding proteins have not previously
been considered as autoantigens. In the present study, we
identified novel autoantibodies against a set of at least five
proteins recovered in high salt eluates of poly(IC)-agarose af-
finity columns (Fig. 7), suggesting that they are dsRNA-bind-
ing factors.
The 90- and 45-kDa proteins were shown to be NF90zNF45,
a heterodimer initially isolated as a nuclear factor that binds to
the AARE element of the human interleukin-2 promoter (11).
The DNA binding activity of this factor is augmented by iono-
mycin plus phorbol 12-myristate 13-acetate and inhibited by
cyclosporin or FK506 (10). More recently, NF90zNF45 was
found to bind selectively to the adenoviral VA RNAII (8), sug-
gesting that it also binds to dsRNA. Consistent with that pos-
sibility, NF90 has sequence similarity at positions 419–464
and 535–604 to the dsRNA-binding site of Drosophila Staufen,
human PKR, human trans-activation-responsive RNA-binding
protein, and other proteins with a conserved dsRNA-binding
motif (10). It recently has been shown to exhibit dsRNA binding
activity and to be phosphorylated in a dsRNA-dependent man-
ner, possibly by interferon-induced PKR (23). NF90 is highly
homologous with MPP4 and Xenopus dsRNA-binding protein
FIG. 7. NF45zNF90 complexes bind to dsRNA as well as DNA.
[35S]Methionine-labeled K562 cell extract was incubated with poly(IC)-
agarose, ssDNA cellulose, or dsDNA cellulose, and bound proteins were
eluted with 1.5 M NaCl NET/Nonidet P-40. Whole K562 cell extract or
proteins eluted from dsRNA poly(IC)-agarose, ssDNA, or dsDNA cellu-
lose were immunoprecipitated with human sera containing anti-
NF45zNF90 (lanes 1 of each panel), anti-Ku plus anti-nRNP/Sm (lanes
2), or with normal human serum (lanes 3). Note the presence of
NF45zNF90 complexes in eluates from dsRNA, as well as the ssDNA
and dsDNA affinity matrices (lanes 1). In contrast, Ku70zKu80 com-
plexes (DNA-binding protein complex) were found only in the eluates
from ssDNA and dsDNA affinity matrices (lanes 2).
FIG. 6. Autoantibodies to p110 and p90 are cross-reactive. The
p130, p110, p90, and p45 proteins were affinity-purified, fractionated by
SDS-PAGE, and transferred to nitrocellulose. After staining with Pon-
ceau red, bands at 130, 110, 90, and 45 kDa and an unrelated area of the
blot were cut out of the membrane. The individual protein bands were
incubated with autoimmune serum, and bound antibodies were affinity-
purified and used to reprobe strips of the original blot. Affinity-purified
antibodies to p110 (lanes 3) and p90 (lanes 4) bound to both p110 and
p90, suggesting that these antibodies are cross-reactive. Panel a, serum
from a pristane-treated B6 mouse. Panel b, serum from a B10.S mouse
treated with pristane. Individual lanes were probed with the following:
lane 1, starting serum (without affinity purification); lane 2, antibodies
affinity-purified from p130; lane 3, antibodies affinity-purified from
p110; lane 4, antibodies affinity-purified from p90; lane 5, antibodies
affinity-purified from p45; lane 6, antibodies affinity-purified from ir-
relevant region of the blot; lane 7, serum from a PBS-treated mouse.
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(62% identical) (17, 24). RNA helicase A, a 140-kDa dsRNA-
binding factor that interacts selectively with VA RNAII, also
appears to be the target of autoantibodies in pristane-induced
lupus as well as human autoimmune disease.3
Another dsRNA-binding factor, p110, had an identical N-
terminal amino acid sequence (Fig. 2) and exhibits immunolog-
ical cross-reactivity with NF90 (Fig. 6). This protein could be
either a precursor or an alternative form of NF90 or a different
protein, possibly MPP4, which has a size of ;110 kDa (17). The
relationship between NF90, MPP4, and p110 is uncertain be-
cause the full-length sequence of MPP4 has not been reported,
and most antisera recognize both 90 and 110 kDa proteins. In
view of the striking sequence homology between the revised
NF90 cDNA sequence and the partial MPP4 sequences,4 it is
very possible that NF90 and p110 are transcribed from the
same mRNA. The p110-specific serum shown in Fig. 5A (lane 3)
may be useful for investigating this possibility.
The p130 and p80 dsRNA-binding autoantigens remain un-
identified. There are several other proteins with sequence ho-
mology/similarity to the dsRNA-binding motifs of NF90, in-
cluding dsRNA adenosine deaminase (2). This protein has 150-
and 110-kDa isoforms, the former potentially a candidate for
p130. However, the interferon-dependent expression of the
150-kDa dsRNA adenosine deaminase (2) argues against that
possibility. There are numerous additional proteins exhibiting
alignment scores ,40, including ribonuclease III, protamine-1
RNA-binding protein, HIV-1 trans-activation-responsive RNA-
binding protein, and PKR.
Although relatively common in certain strains of mice, au-
toantibodies to NF90zNF45, p110, p130, and p80 are unusual in
humans. We screened over 1200 sera and found only two with
anti-NF90zNF45 autoantibodies. One of the patients had
scleroderma and the other systemic lupus erythematosus-rheu-
matoid arthritis overlap syndrome without features of sclero-
derma. Labrador et al. (25) recently have reported three addi-
tional patients with rheumatoid arthritis and features of
scleroderma who produced autoantibodies against proteins of
105, 95, and 42 kDa (25). Exchange of sera suggests that these
antigens are NF90zNF45 and p110.5
NF45 Forms Complexes with NF90 and p110—NF90 is
thought to dimerize with NF45 (10, 11), an interpretation con-
sistent with the co-immunoprecipitation data presented here
(Fig. 5). Interpretation of the interactions of p110 with other
dsRNA-binding factors is complicated by the immunological
cross-reactivity of p110 with NF90 (Fig. 6). Nevertheless, by
analyzing autoantibody production longitudinally, we found
that autoantibodies against p110 occasionally developed in the
absence of anti-NF90 and that they co-immunoprecipitated
NF45 (Fig. 5A). Moreover, purified anti-NF45 antibodies co-
immunoprecipitated p110. We conclude that like the homolo-
gous NF90, p110 may dimerize with NF45. Labrador et al. (25)
also described complex formation (25). Based on immunopre-
cipitation with affinity purified antibodies, these investigators
concluded that all three components form a single complex.
Immunological cross-reactivity of anti-NF90 and p110 compli-
cates the interpretation of this experiment, however. Although
we cannot exclude a trimer, the present data (Fig. 5) are more
compatible with the alternative explanation that there are both
NF90zNF45 and p110zNF45 dimers.
At present, there is no evidence that p130 forms a stable
complex with NF90, NF45, or p110. EB serum immunoprecipi-
tated p110, NF90, and NF45 but not p130 (Fig. 1). Even under
low salt conditions, co-immunoprecipitation was not seen (data
not shown). Moreover, p130 was eluted from poly(IC)-agarose
at lower salt than p110, NF90, or NF45. Thus, if an interaction
exists, it is either transient or else unstable under the condi-
tions used for immunoprecipitation.
Nucleic Acid-binding Properties of NF90zNF45, p110, and
3 H. Yoshida, M. Satoh, and W. H. Reeves, manuscript in preparation.
4 P. N. Kao, unpublished data.
5 C Gelpi, personal communication.
FIG. 8. DNA and dsRNA inhibit autoantibody binding. A and B,
microtiter plate wells were coated with recombinant NF90 or NF45 and
incubated with ssDNA or poly(IC) at indicated concentrations. Wells
were washed and incubated with 1:500 sera from a B6 (A) or a B10.S (B)
mouse and then incubated with 1:1000 alkaline phosphatase-conju-
gated goat anti-mouse IgG (g-chain specific) antibodies. Inhibition was
calculated as described under “Experimental Procedures.” Closed cir-
cles, inhibition with ssDNA; open circles, inhibition with poly(IC). C,
inhibition of the binding of murine and human autoantibodies to
NF45zNF90 by ssDNA or poly(IC) was tested. Open circles, sera from
pristane-treated mice with anti-NF90zNF45 antibodies; closed circle,
human autoimmune serum YM. D, inhibition of the binding of individ-
ual sera to NF90 by ssDNA (x axis) and poly(IC) (y axis). Open circles,
murine autoimmune sera; closed circle, patient YM serum.
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p130—The NF90zNF45 complex has sequence-specific DNA
binding (10, 11) as well as nonspecific and VA RNAII-selective
dsRNA binding activity (8). The present data indicating strong
binding to poly(IC) and dsDNA from calf thymus (Fig. 7) are
consistent with the previous reports. The p110 protein, proba-
bly in the form of a p110zNF45 dimer, showed similar nucleic
acid binding properties but bound to ssDNA more efficiently
than did NF90zNF45. In contrast, p130 bound efficiently to
poly(IC), although less tightly than p110, NF90, or NF45, and
also bound weakly to dsDNA but not ssDNA (Fig. 7). These
data suggest that some dsRNA-binding autoantigens can inter-
act with DNA as well as RNA. Other proteins with dual RNA
and DNA binding activity have been described (26–28). Little
is known about the mechanisms of dsRNA or DNA binding,
although it is possible that the dsRNA-binding motifs of NF90
interact with dsRNA in a manner analogous to that of PKR
(29). This may account for the high avidity of the NF90zNF45
interaction with dsRNA. Interestingly, the antibody inhibition
studies (Fig. 8) suggest that the site(s) contacting dsRNA differ
from those contacting DNA. The same is true of the DNA and
RNA-binding sites of dsRNA adenosine deaminase (28). How-
ever, the domain-mediating interactions of NF90zNF45 with
DNA have not yet been defined.
Relevance to Autoimmune Disease—The binding of dsDNA
and dsRNA to p110, NF90, and NF45 may have implications
for the pathogenesis of autoimmune disease. Because these
proteins are constitutively expressed, they could play an early
role in the cellular mechanisms for sensing ds nucleic acids
resulting from viral infection or the escape of genomic or mito-
chondrial DNA into the cytoplasm in injured cells. Transfection
of either dsRNA or dsDNA induces the expression of several
genes involved in antigen processing and presentation, includ-
ing class I and class II major histocompatibility complex anti-
gens (30). Moreover, activation of the Jak/Stat, NF-kB, and
MAPK systems is induced by transfection of dsRNA, poten-
tially establishing a proinflammatory cytokine milieu condu-
cive to the development of autoimmunity. There is considerable
evidence that viral infections can promote autoimmunity (31–
33). This may reflect the production of proinflammatory cyto-
kines such as interleukin-12 (34), molecular mimicry (35),
and/or the binding of virally encoded proteins to self-antigens
(36). The possibility exists that binding of viral dsRNA to
NF90zNF45, p110, or p130 might induce autoimmunity to these
proteins, analogous to the development of high levels of autoan-
tibodies to p53 in mice immunized with complexes of mouse p53
and SV40 large T antigen (36). The adjuvant-like properties of
dsRNA also could promote autoimmunity.
In summary, a family of constitutively expressed dsRNA-
binding proteins is recognized by autoantibodies produced in
systemic autoimmune disease. Using the autoimmune sera,
some of these proteins were shown to assemble into complexes
that bind DNA as well as dsRNA. In some cases, DNA but not
dsRNA inhibited autoantibody binding to NF90. In other cases,
the reverse was true, suggesting that different sites mediate
the interactions with DNA and dsRNA. Although the function
of these proteins remains unclear, their constitutive expression
and interactions with VA RNAII and possibly other highly
structured viral RNAs permit speculation that they may play a
role in sensing the presence of viral infection.
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